Gastric Cancer in the TNT Era: Have We Resolved the Timing Dilemma?
Background
Perioperative chemotherapy has become standard care for locally advanced resectable gastric cancer, significantly improving outcomes compared to surgery alone. However, the optimal timing for administering systemic therapy remains unclear, with differing methodologies between Western and East Asian research traditions. Western studies primarily focus on the neoadjuvant component, while East Asian studies emphasize the benefits of adjuvant therapy following high-quality D2 surgery.
Data Highlights
No specific numerical data or trial results were provided in the source material.
Key Findings
Perioperative chemotherapy improves outcomes in locally advanced gastric cancer.
Western studies focus on the neoadjuvant component, while East Asian studies emphasize adjuvant therapy post-surgery.
Most landmark trials did not evaluate treatment timing as an independent variable.
There is a shift towards total neoadjuvant therapy (TNT) with more systemic treatment delivered preoperatively.
Confirmatory phase III evidence isolating treatment timing is currently lacking.
Clinical Implications
Clinicians should be aware of the ongoing debate regarding the timing of systemic therapy in gastric cancer treatment. Future studies are needed to determine the independent benefits of treatment timing, which may influence clinical decision-making and patient management.
Conclusion
The timing of systemic therapy in gastric cancer treatment remains an unresolved issue that warrants further investigation to clarify its independent oncological benefits.
